COPD

News

Teva’s smart inhaler launches in first European market

Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disord

News

Sanofi, Regeneron flesh out COPD data with Dupixent

Sanofi and Regeneron have built their case for Dupixent as a first biological therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (AT

News

Sanofi, Regeneron’s wager on Dupixent in COPD pays off

Approval in COPD could unlock a $3 billion market opportunity for the drug, say analysts.

Patients

The invisible burden of RSV on older adults

As we continue to move beyond the COVID-19 pandemic, we’ve seen many aspects of life returning to normal.

News

AstraZeneca, C4XD sign exclusive $402 million global licence

C4X Discovery Holdings has signed an exclusive global licence worth up to $402 million with AstraZeneca (AZ) for the development and commercialisation of the NRF2 Activator programme.

Digital

Health Innovators – Sai Shankar and Pierre Leurent

At Frontiers Health 2022, pharmaphorum Editor in Chief Jonah Comstock speaks with Sai Shankar and Pierre Leurent, co-presidents of Aptar Digital Health. They discuss their new part

Teva’s smart inhaler launches in first European market

Sanofi, Regeneron flesh out COPD data with Dupixent

Sanofi, Regeneron’s wager on Dupixent in COPD pays off

The invisible burden of RSV on older adults

AstraZeneca, C4XD sign exclusive $402 million global licence

Health Innovators – Sai Shankar and Pierre Leurent

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

COPD

Editor's Picks